MSK Controversies in Gastrointestinal Premalignant and Malignant Disorders - 2020
MSK Controversies in Gastrointestinal Premalignant and Malignant Disorders - 2020 is organized by Memorial Sloan Kettering Cancer Center (MSKCC) and will be held on Apr 03, 2020 at Memorial Sloan Kettering Cancer Center - Zuckerman Research Center, New York City, New York, United States of America.
Early recognition and management of premalignant gastrointestinal disorders are important in the prevention and early detection of cancer. With advances in our understanding of the pathogenesis and natural history of premalignant and malignant GI disorders, treatment algorithms continue to evolve. Emerging endoscopic techniques also play an important role in the diagnosis and management of these patients.
This one day course will update the participant on current controversies regarding the diagnosis, management and surveillance of GI premalignant and malignant disorders involving the upper and lower GI tracts, liver and pancreaticobiliary tracts. Topics will include Barrett’s esophagus, gastric intestinal metaplasia, early esophageal cancer, early gastric cancer, hepatocellular carcinoma, pancreas cyst lesions, malignant hilar biliary obstruction, ampullary adenoma, colon cancer screening, fecal immunochemical test (FIT)-DNA stool testing, IBD and dysplasia, large colon polyps, Lynch syndrome chemoprevention, upper GI tract screening in Lynch syndrome, hereditary gastric cancer, and pancreas cancer screening in high-risk populations. The course will utilize didactic lectures as well as clinical case presentations.
The target audience for this course includes physicians and other healthcare professionals who take care of patients with gastrointestinal, liver and pancreaticobiliary disorders, including gastroenterologists, surgical oncologists, medical oncologists, interventional radiologists, clinical geneticists, fellows, residents, physician assistants, nurse practitioners and registered nurses.
• Review the diagnosis and management of Barrett's esophagus, including endoscopic therapy for dysplasia.
• Become familiar with the diagnosis and management of gastric metaplasia, dysplasia
• Understand the diagnosis and management of early esophageal and gastric cancer
• Become aware of surveillance strategies for hepatocellular carcinoma.
• Recognize medical and surgical management options for pancreas cyst lesions.
• Discuss the role of endoscopic and interventional radiology management of malignant hilar biliary obstruction.
• Describe the indications for and endoscopic management of ampullary adenoma.
• Examine when to start and stop screening for colon cancer.
• Determine clinical management after fecal immunochemical test (FIT)-DNA stool testing.
• Review endoscopic and surgical management options for inflammatory bowel disease-associated colorectal dysplasia.
• Evaluate endoscopic techniques for treating large colon polyps.
• Discuss role for chemoprevention and upper GI tract screening in Lynch syndrome.
• Recognize endoscopic surveillance and surgical management options for hereditary gastric cancer.
• Examine the role of pancreas cancer screening in high-risk populations
Live Simulcast Available*
We are pleased to offer a live simulcast for this course, available to non-MSK employees. CME and ABIM MOC credit is offered for the live simulcast and active participation is required throughout the course. We do hope you will attend in person but understand that can sometimes be a challenge, so we are happy to offer the live simulcast as an option. Registration for the simulcast is required; please select the "Live Simulcast" option during course registration. A link to view the course will be emailed to you the day before the course begins.
|Contact No. :||646-227-2025
|Registration Type||Last Date||Price|
|Physicians (MDs, PhDs and DOs) Fee||03 Apr,2020||USD 250.00|
|Residents, Fellows, Advanced Practice Providers, Nurses, and Other Healthcare Providers Fee||03 Apr,2020||USD 175.00|
|Industry Professionals Fee||03 Apr,2020||USD 450.00|
|Live Simulcast Fee||03 Apr,2020||USD 450.00|